Skip to main content

Nymi bands by Toronto-based Bionym.

Bionym

Toronto startup Bionym has closed a $14-million (U.S.) funding round led by a number of high-profile investors, including Relay Ventures, Export Development Canada (EDC) and MasterCard.

Bionym has developed a wearable product called the Nymi band, which authenticates a user's identity by heartbeat, or unique ECG. It can be used with applications that require passwords, PINs and keycards. The company has logged more than 10,000 pre-orders with a release scheduled for the fall.

"Bionym is a game-changer in that (it is) the only one putting ownership of authentication into the hands of the consumer," said John Albright, co-founder and managing partner of Relay Ventures, which also participated in Bionym's seed round.

Story continues below advertisement

The latest investment – in which Ignition Partners and Salesforce Ventures also contributed – was a Series A round, funding that often still carries high risk, but tends to occur when a company is starting to generate some revenue. Bionym currently employs about 40 people.

"We're establishing the Nymi as the de facto platform for persistent, trusted identity, and this round of financing is providing us with the resources needed to bring the platform to market," Karl Martin, CEO and founder of Bionym, said in a press release.

"We're at the forefront of a revolution in identity-based interactions with devices and services, and our momentum continues to grow with the support of our investors and strategic partners."

Follow Report on Small Business on Pinterest and Instagram
Join our Small Business LinkedIn group
Add us to your circles
Sign up for our weekly newsletter

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter